172 related articles for article (PubMed ID: 36678809)
1. Gliadin Nanoparticles Containing Doxorubicin Hydrochloride: Characterization and Cytotoxicity.
Voci S; Gagliardi A; Ambrosio N; Salvatici MC; Fresta M; Cosco D
Pharmaceutics; 2023 Jan; 15(1):. PubMed ID: 36678809
[TBL] [Abstract][Full Text] [Related]
2. Development of polyoxyethylene (2) oleyl ether-gliadin nanoparticles: Characterization and in vitro cytotoxicity.
Voci S; Gagliardi A; Salvatici MC; Fresta M; Cosco D
Eur J Pharm Sci; 2021 Jul; 162():105849. PubMed ID: 33857638
[TBL] [Abstract][Full Text] [Related]
3. Ascorbic acid-loaded gliadin nanoparticles as a novel nutraceutical formulation.
Voci S; Gagliardi A; Fresta M; Cosco D
Food Res Int; 2022 Nov; 161():111869. PubMed ID: 36192989
[TBL] [Abstract][Full Text] [Related]
4. Effect of Chemical Binding of Doxorubicin Hydrochloride to Gold Nanoparticles, Versus Electrostatic Adsorption, on the In Vitro Drug Release and Cytotoxicity to Breast Cancer Cells.
Zayed GM; Kamal I; Abdelhafez WA; M Alsharif F; Amin MA; Shaykoon MSA; Sarhan HA; Abdelsalam AM
Pharm Res; 2018 Mar; 35(6):112. PubMed ID: 29603025
[TBL] [Abstract][Full Text] [Related]
5. Design and evaluation of a novel potential carrier for a hydrophilic antitumor drug: Auricularia auricular polysaccharide-chitosan nanoparticles as a delivery system for doxorubicin hydrochloride.
Xiong W; Li L; Wang Y; Yu Y; Wang S; Gao Y; Liang Y; Zhang G; Pan W; Yang X
Int J Pharm; 2016 Sep; 511(1):267-275. PubMed ID: 27424168
[TBL] [Abstract][Full Text] [Related]
6. Development and Evaluation of Core-Shell Nanocarrier System for Enhancing the Cytotoxicity of Doxorubicin/Metformin Combination Against Breast Cancer Cell Line.
Ibrahim A; Khalil IA; El-Sherbiny IM
J Pharm Sci; 2022 Sep; 111(9):2581-2591. PubMed ID: 35613685
[TBL] [Abstract][Full Text] [Related]
7. Effects of doxorubicin mediated by gold nanoparticles and resveratrol in two human cervical tumor cell lines.
Tomoaia G; Horovitz O; Mocanu A; Nita A; Avram A; Racz CP; Soritau O; Cenariu M; Tomoaia-Cotisel M
Colloids Surf B Biointerfaces; 2015 Nov; 135():726-734. PubMed ID: 26340362
[TBL] [Abstract][Full Text] [Related]
8. Development of novel self-assembled ES-PLGA hybrid nanoparticles for improving oral absorption of doxorubicin hydrochloride by P-gp inhibition: In vitro and in vivo evaluation.
Wang J; Li L; Wu L; Sun B; Du Y; Sun J; Wang Y; Fu Q; Zhang P; He Z
Eur J Pharm Sci; 2017 Mar; 99():185-192. PubMed ID: 27989702
[TBL] [Abstract][Full Text] [Related]
9. The comparative effect of wrapping solid gold nanoparticles and hollow gold nanoparticles with doxorubicin-loaded thermosensitive liposomes for cancer thermo-chemotherapy.
Li Y; He D; Tu J; Wang R; Zu C; Chen Y; Yang W; Shi D; Webster TJ; Shen Y
Nanoscale; 2018 May; 10(18):8628-8641. PubMed ID: 29697100
[TBL] [Abstract][Full Text] [Related]
10. Preclinical development of carrier-free prodrug nanoparticles for enhanced antitumor therapeutic potential with less toxicity.
Shim MK; Yang S; Park J; Yoon JS; Kim J; Moon Y; Shim N; Jo M; Choi Y; Kim K
J Nanobiotechnology; 2022 Oct; 20(1):436. PubMed ID: 36195911
[TBL] [Abstract][Full Text] [Related]
11. Anti-CD44 and EGFR Dual-Targeted Solid Lipid Nanoparticles for Delivery of Doxorubicin to Triple-Negative Breast Cancer Cell Line: Preparation, Statistical Optimization, and
Darabi F; Saidijam M; Nouri F; Mahjub R; Soleimani M
Biomed Res Int; 2022; 2022():6253978. PubMed ID: 35845934
[TBL] [Abstract][Full Text] [Related]
12. A new combination strategy to enhance apoptosis in cancer cells by using nanoparticles as biocompatible drug delivery carriers.
Kucuksayan E; Bozkurt F; Yilmaz MT; Sircan-Kucuksayan A; Hanikoglu A; Ozben T
Sci Rep; 2021 Jun; 11(1):13027. PubMed ID: 34158544
[TBL] [Abstract][Full Text] [Related]
13. Increased Toxicity of Doxorubicin Encapsulated into pH-Responsive Poly(β-Amino Ester)-Functionalized MCM-41 Silica Nanoparticles.
Ávila-Ortega A; Carrillo-Cocom LM; Olán-Noverola CE; Nic-Can GI; Vilchis-Nestor AR; Talavera-Pech WA
Curr Drug Deliv; 2020; 17(9):799-805. PubMed ID: 32723272
[TBL] [Abstract][Full Text] [Related]
14. Enhanced tumor delivery and antitumor response of doxorubicin-loaded albumin nanoparticles formulated based on a Schiff base.
Li F; Zheng C; Xin J; Chen F; Ling H; Sun L; Webster TJ; Ming X; Liu J
Int J Nanomedicine; 2016; 11():3875-90. PubMed ID: 27574421
[TBL] [Abstract][Full Text] [Related]
15. Co-delivery of doxorubicin, docosahexaenoic acid, and α-tocopherol succinate by nanostructured lipid carriers has a synergistic effect to enhance antitumor activity and reduce toxicity.
Lages EB; Fernandes RS; Silva JO; de Souza ÂM; Cassali GD; de Barros ALB; Miranda Ferreira LA
Biomed Pharmacother; 2020 Dec; 132():110876. PubMed ID: 33113428
[TBL] [Abstract][Full Text] [Related]
16. Nano-delivery vehicle based on chlorin E6, photodynamic therapy, doxorubicin chemotherapy provides targeted treatment of HER-2 negative, ανβ3-positive breast cancer.
He Z; Jiang H; Zhang X; Zhang H; Cui Z; Sun L; Li H; Qian J; Ma J; Huang J
Pharmacol Res; 2020 Oct; 160():105184. PubMed ID: 32946931
[TBL] [Abstract][Full Text] [Related]
17. Preparation of Modified Chitosan-based Nanoparticles for Efficient Delivery of Doxorubicin and/or Cisplatin to Breast Cancer Cells.
Matalqah SM; Aiedeh K; Mhaidat NM; Alzoubi KH; Al-Husein BA
Curr Cancer Drug Targets; 2022; 22(2):133-141. PubMed ID: 35081892
[TBL] [Abstract][Full Text] [Related]
18. The chemotherapeutic potential of doxorubicin-loaded PEG-b-PLGA nanopolymersomes in mouse breast cancer model.
Alibolandi M; Sadeghi F; Abnous K; Atyabi F; Ramezani M; Hadizadeh F
Eur J Pharm Biopharm; 2015 Aug; 94():521-31. PubMed ID: 26170161
[TBL] [Abstract][Full Text] [Related]
19. Characterization and Evaluation of Bone-Derived Nanoparticles as a Novel pH-Responsive Carrier for Delivery of Doxorubicin into Breast Cancer Cells.
Haque ST; Islam RA; Gan SH; Chowdhury EH
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32937817
[No Abstract] [Full Text] [Related]
20. A self-assembled polyjuglanin nanoparticle loaded with doxorubicin and anti-Kras siRNA for attenuating multidrug resistance in human lung cancer.
Wen ZM; Jie J; Zhang Y; Liu H; Peng LP
Biochem Biophys Res Commun; 2017 Dec; 493(4):1430-1437. PubMed ID: 28958938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
